J.P. Droz

1.5k total citations
26 papers, 315 citations indexed

About

J.P. Droz is a scholar working on Surgery, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, J.P. Droz has authored 26 papers receiving a total of 315 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Surgery, 7 papers in Pulmonary and Respiratory Medicine and 7 papers in Oncology. Recurrent topics in J.P. Droz's work include Testicular diseases and treatments (7 papers), Multiple and Secondary Primary Cancers (5 papers) and Cancer Diagnosis and Treatment (4 papers). J.P. Droz is often cited by papers focused on Testicular diseases and treatments (7 papers), Multiple and Secondary Primary Cancers (5 papers) and Cancer Diagnosis and Treatment (4 papers). J.P. Droz collaborates with scholars based in France, United Kingdom and United States. J.P. Droz's co-authors include A. Gerl, Karim Fizazi, J. Beyer, Hartmut Hecker, J. Pont, Craig R. Nichols, Pierre Biron, A. Horwich, C. Bokemeyer and J. T. Hartmann and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and British Journal of Cancer.

In The Last Decade

J.P. Droz

25 papers receiving 305 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
J.P. Droz France 7 147 92 86 81 72 26 315
P Vennin France 10 45 0.3× 168 1.8× 36 0.4× 21 0.3× 61 0.8× 23 359
R. M. Bremnes Norway 4 81 0.6× 151 1.6× 24 0.3× 16 0.2× 28 0.4× 15 308
Reem Al‐Saadi United Kingdom 11 117 0.8× 42 0.5× 40 0.5× 29 0.4× 40 0.6× 22 403
E S Mayall United Kingdom 4 55 0.4× 174 1.9× 92 1.1× 14 0.2× 99 1.4× 6 497
J.R. Germà Spain 12 385 2.6× 82 0.9× 20 0.2× 100 1.2× 13 0.2× 27 520
Akihito Nishio Japan 9 170 1.2× 134 1.5× 23 0.3× 57 0.7× 10 0.1× 18 376
Ricardo López Almaraz Spain 11 97 0.7× 43 0.5× 31 0.4× 66 0.8× 13 0.2× 43 267
M Abrate Italy 11 46 0.3× 49 0.5× 34 0.4× 16 0.2× 26 0.4× 25 368
J Guerrin France 10 63 0.4× 187 2.0× 132 1.5× 16 0.2× 24 0.3× 43 332
Maria Koumpou Greece 8 146 1.0× 139 1.5× 26 0.3× 34 0.4× 6 0.1× 12 321

Countries citing papers authored by J.P. Droz

Since Specialization
Citations

This map shows the geographic impact of J.P. Droz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J.P. Droz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J.P. Droz more than expected).

Fields of papers citing papers by J.P. Droz

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J.P. Droz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J.P. Droz. The network helps show where J.P. Droz may publish in the future.

Co-authorship network of co-authors of J.P. Droz

This figure shows the co-authorship network connecting the top 25 collaborators of J.P. Droz. A scholar is included among the top collaborators of J.P. Droz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J.P. Droz. J.P. Droz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Massard, Christophe & J.P. Droz. (2010). Problématique des tumeurs rares : une nouvelle rubrique du Bulletin du cancer. Bulletin du Cancer. 97(9). 1031–1039.
2.
Joniau, Steven, Lodovico Balducci, M. Bolla, et al.. (2008). SIOG (INTERNATIONAL SOCIETY OF GERIATRIC ONCOLOGY). European Urology Supplements. 7(3). 300. 1 indexed citations
3.
Droz, J.P., Lodovico Balducci, M. Bolla, et al.. (2007). VIA.1 SIOG (International Society of Geriatric Oncology) prostate cancer guidelines proposals in senior adult men. Critical Reviews in Oncology/Hematology. 64. S20–S20. 5 indexed citations
4.
Albrand, G., et al.. (2005). Early breast cancer in elderly women: The value of Comprehensive Geriatric Assessment (CGA). Journal of Clinical Oncology. 23(16_suppl). 8172–8172. 2 indexed citations
5.
Joly, Florence, Nadine Tchen, Christine Chevreau, et al.. (2004). Clinical benefit of second line weekly paclitaxel in advanced urothelial carcinoma (AUC): A GETUG phase II study. Journal of Clinical Oncology. 22(14_suppl). 4619–4619. 7 indexed citations
6.
Jonge, Maja J. De, Ingrid Glimelius, Jaap Verweij, et al.. (2002). Effects of impaired renal function on the pharmacokinetics and toxicity of i.v. ZD9331, a novel non-polyglutamated thymidylate synthase inhibitor, in adult patients with solid tumors. Anti-Cancer Drugs. 13(6). 645–653. 3 indexed citations
7.
Ramaioli, A., C Théodore, M.-J. Terrier-Lacombe, et al.. (2001). Non-Hodgkin’s lymphoma of the testis: A retrospective study of 84 patients treated in the French anticancer centres. Annals of Oncology. 12(9). 1313–1315. 44 indexed citations
8.
Hartmann, J. T., S.D. Fosså, Craig R. Nichols, et al.. (2001). Incidence of Metachronous Testicular Cancer in Patients With Extragonadal Germ Cell Tumors. JNCI Journal of the National Cancer Institute. 93(22). 1733–1738. 121 indexed citations
9.
Fumoleau, P., Hoffmann-La Roche, Christian Dittrich, et al.. (2000). Combined results of 4 phase I and pharmacokinetic (PK) studies of E7070, a novel chloroindolyl-sulphonamide inhibiting the activation of cdk2 and cyclin E. UCL Discovery (University College London). 7 indexed citations
10.
Droz, J.P., A.-R. Hanauske, Jaap Verweij, et al.. (1998). Broad phase II and pharmacokinetic study of methoxy-morpholino doxorubicin (FCE 23762-MMRDX) in non-small-cell lung cancer, renal cancer and other solid tumour patients. British Journal of Cancer. 77(1). 139–146. 13 indexed citations
11.
12.
Houlgatte, A., et al.. (1998). [Survival and quality of life of patients with testicular cancer].. PubMed. 32(2). 80–2. 1 indexed citations
13.
Farhat, Fadi, et al.. (1995). [Adenocarcinoma of rete testis. Apropos of a case and review of the literature].. PubMed. 82(2). 167–72. 1 indexed citations
14.
Terrier-Lacombe, M.-J., Joseph Kattan, Alain Cazier, et al.. (1994). [Primary, highly malignant B-cell lymphoma of the prostate. Apropos of a case and review of the literature].. PubMed. 81(4). 334–7. 4 indexed citations
15.
Droz, J.P., Pierre Biron, Pierre Kerbrat, et al.. (1993). Early Intensified Chemotherapywith AutologousBone Marrow Transplantation inFirst Line Treatment ofPoor Risk Non-SeminomatousGerm Cell Tumours. European Urology. 23(1). 213–218. 69 indexed citations
16.
Maulard, C, et al.. (1993). Phase I-II study of the somatostatin analogue somatulin in hormone refractory prostatic cancer (HRPC). European Journal of Cancer. 29. S237–S237. 2 indexed citations
17.
Mahjoubi, M., et al.. (1992). Phase II trial of pirarubicin in the treatment of advanced bladder cancer. Investigational New Drugs. 10(4). 317–321. 5 indexed citations
18.
Rougier, Philippe, Mohamed Azab, M. Henry‐Amar, et al.. (1990). [Primitive digestive localizations of malignant non-Hodgkin's lymphoma. Prognostic factors of locally advanced disease: stage II. Report of 67 cases].. PubMed. 14(8-9). 626–34. 1 indexed citations
19.
Baldeyrou, P, et al.. (1985). Surgical treatment for thoracic metastases from malignant germ cell tumors of the testes.. PubMed. 203. 353–6. 1 indexed citations
20.
Rougier, P, et al.. (1984). Chimiothérapie des métastases hépatiques isolées. Utilisation d'un réservoir sous-cutané pour infusions intra-artérielles.. La Presse Médicale. 13(10). 620–620. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by P Vennin Breakdown of academic impact, for papers by R. M. Bremnes Breakdown of academic impact, for papers by Reem Al‐Saadi Breakdown of academic impact, for papers by E S Mayall Breakdown of academic impact, for papers by J.R. Germà Breakdown of academic impact, for papers by Akihito Nishio Breakdown of academic impact, for papers by Ricardo López Almaraz Breakdown of academic impact, for papers by M Abrate Breakdown of academic impact, for papers by J Guerrin Breakdown of academic impact, for papers by Maria Koumpou
Rankless by CCL
2026